Cargando…

Prediction of primary non-response to methotrexate therapy using demographic, clinical and psychosocial variables: results from the UK Rheumatoid Arthritis Medication Study (RAMS)

BACKGROUND: Methotrexate (MTX) remains the disease-modifying anti-rheumatic drug of first choice in rheumatoid arthritis (RA) but response varies. Predicting non-response to MTX could enable earlier access to alternative or additional medications and control of disease progression. We aimed to ident...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sergeant, Jamie C., Hyrich, Kimme L., Anderson, James, Kopec-Harding, Kamilla, Hope, Holly F., Symmons, Deborah P. M., Barton, Anne, Verstappen, Suzanne M. M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6044018/ https://www.ncbi.nlm.nih.gov/pubmed/30005689 http://dx.doi.org/10.1186/s13075-018-1645-5

Ejemplares similares

Psychological factors predict adherence to methotrexate in rheumatoid arthritis; findings from a systematic review of rates, predictors and associations with patient-reported and clinical outcomes
por: Hope, Holly F, et al.
Publicado: (2016)

Rates and predictors of methotrexate-related adverse events in patients with early rheumatoid arthritis: results from a nationwide UK study
por: Sherbini, Ahmad A, et al.
Publicado: (2022)

Changes in the illness perceptions of patients with rheumatoid arthritis over the first year of methotrexate therapy
por: Gwinnutt, James M, et al.
Publicado: (2020)

Differential DNA methylation correlates with response to methotrexate in rheumatoid arthritis
por: Nair, Nisha, et al.
Publicado: (2020)

Profiling of Gene Expression Biomarkers as a Classifier of Methotrexate Nonresponse in Patients With Rheumatoid Arthritis
por: Plant, Darren, et al.
Publicado: (2019)

Do people with rheumatoid arthritis maintain their physical activity level at treatment onset over the first year of methotrexate therapy?
por: Gwinnutt, James M, et al.
Publicado: (2021)

Predictors of presenteeism, absenteeism and job loss in patients commencing methotrexate or biologic therapy for rheumatoid arthritis
por: Gwinnutt, James M, et al.
Publicado: (2020)

Prediction of response of methotrexate in patients with rheumatoid arthritis using serum lipidomics
por: Maciejewski, Mateusz, et al.
Publicado: (2021)

The incidence of rheumatoid arthritis in the UK: comparisons using the 2010 ACR/EULAR classification criteria and the 1987 ACR classification criteria. Results from the Norfolk Arthritis Register
por: Humphreys, Jennifer H, et al.
Publicado: (2013)

Long-term persistence with rituximab in patients with rheumatoid arthritis
por: Oldroyd, Alexander G S, et al.
Publicado: (2018)

Risk factors for oral methotrexate failure in patients with inflammatory polyarthritis: results from a UK prospective cohort study
por: Bluett, James, et al.
Publicado: (2018)

What is the impact of biologic therapies on common co-morbidities in patients with rheumatoid arthritis?
por: Humphreys, Jenny, et al.
Publicado: (2016)

Long-term outcomes of patients who rate symptoms of rheumatoid arthritis as ‘satisfactory’
por: Gwinnutt, James M, et al.
Publicado: (2020)

Working status in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: results from the British Society for Rheumatology Biologics Register
por: Verstappen, Suzanne M. M., et al.
Publicado: (2010)

Not all moderate disease is the same – Identification of disability trajectories among patients with rheumatoid arthritis and moderate disease activity
por: Pan, Yi, et al.
Publicado: (2019)

Correction: Not all moderate disease is the same – Identification of disability trajectories among patients with rheumatoid arthritis and moderate disease activity
por: Pan, Yi, et al.
Publicado: (2020)

Anti-TNF therapies and pregnancy: outcome of 130 pregnancies in the British Society for Rheumatology Biologics Register
por: Verstappen, Suzanne M M, et al.
Publicado: (2011)

Benefit of anti-TNF therapy in rheumatoid arthritis patients with moderate disease activity
por: Hyrich, Kimme L., et al.
Publicado: (2009)

Changes in disease characteristics and response rates among patients in the United Kingdom starting anti-tumour necrosis factor therapy for rheumatoid arthritis between 2001 and 2008
por: Hyrich, Kimme L., et al.
Publicado: (2011)

Prediction of infection risk in rheumatoid arthritis patients treated with biologics: are we any closer to risk stratification?
por: Jani, Meghna, et al.
Publicado: (2019)

Risk of cancer in patients receiving non-biologic disease-modifying therapy for rheumatoid arthritis compared with the UK general population
por: Mercer, Louise K., et al.
Publicado: (2013)

Use and effectiveness of tocilizumab among patients with rheumatoid arthritis: an observational study from the British Society for Rheumatology Biologics Register for rheumatoid arthritis
por: Kihara, Mari, et al.
Publicado: (2016)

No Evidence of Association Between Anti–Tumor Necrosis Factor Treatment and Mortality in Patients With Rheumatoid Arthritis: Results From the British Society for Rheumatology Biologics Register
por: Lunt, Mark, et al.
Publicado: (2010)

Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register
por: Soliman, Moetaza M, et al.
Publicado: (2011)

Venous thrombotic events are not increased in patients with rheumatoid arthritis treated with anti‑TNF therapy: results from the British Society for Rheumatology Biologics Register
por: Davies, Rebecca, et al.
Publicado: (2011)

The predictive value of serum S100A9 and response to etanercept is not confirmed in a large UK rheumatoid arthritis cohort
por: Smith, Samantha Louise, et al.
Publicado: (2017)

Harnessing repeated measurements of predictor variables for clinical risk prediction: a review of existing methods
por: Bull, Lucy M., et al.
Publicado: (2020)

The incidence of cancer in patients with rheumatoid arthritis and a prior malignancy who receive TNF inhibitors or rituximab: results from the British Society for Rheumatology Biologics Register-Rheumatoid Arthritis
por: Silva-Fernández, Lucía, et al.
Publicado: (2016)

Serious infection risk after 1 year between patients with rheumatoid arthritis treated with rituximab or with a second TNFi after initial TNFi failure: results from The British Society for Rheumatology Biologics Register for Rheumatoid Arthritis
por: Silva-Fernández, Lucía, et al.
Publicado: (2018)

The influence of behavioural and psychological factors on medication adherence over time in rheumatoid arthritis patients: a study in the biologics era
por: Morgan, Catharine, et al.
Publicado: (2015)

Proteomic analysis to define predictors of treatment response to adalimumab or methotrexate in rheumatoid arthritis patients
por: Ling, Stephanie F., et al.
Publicado: (2019)

Predictors, demographics and frequency of sustained remission and low disease activity in anti-tumour necrosis factor–treated rheumatoid arthritis patients
por: Hamann, Philip D H, et al.
Publicado: (2019)

Association Between Ischemic Stroke and Tumor Necrosis Factor Inhibitor Therapy in Patients With Rheumatoid Arthritis
por: Low, Audrey S. L., et al.
Publicado: (2016)

Rituximab or a second anti–tumor necrosis factor therapy for rheumatoid arthritis patients who have failed their first anti–tumor necrosis factor therapy? Comparative analysis from the British Society for Rheumatology Biologics Register
por: Soliman, Moetaza M, et al.
Publicado: (2012)

A UK study: vocational experiences of young adults with juvenile idiopathic arthritis
por: Lunt, Laura E., et al.
Publicado: (2019)

Drug-specific risk and characteristics of lupus and vasculitis-like events in patients with rheumatoid arthritis treated with TNFi: results from BSRBR-RA
por: Jani, Meghna, et al.
Publicado: (2017)

Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis
por: Mercer, Louise K, et al.
Publicado: (2015)

The prevalence of co-morbidities and their impact on physical activity in people with inflammatory rheumatic diseases compared with the general population: results from the UK Biobank
por: Cook, Michael J, et al.
Publicado: (2018)

Pre-defined gene co-expression modules in rheumatoid arthritis transition towards molecular health following anti-TNF therapy
por: Sutcliffe, Megan, et al.
Publicado: (2022)

Quantifying the hepatotoxic risk of alcohol consumption in patients with rheumatoid arthritis taking methotrexate
por: Humphreys, Jenny H, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_prbnpald46bo5scpbrq6g8li80